Julien Delrieu

Summary

Country: France

Publications

  1. doi request reprint Gantenerumab for the treatment of Alzheimer's disease
    Julien Delrieu
    Toulouse University Hospital, Alzheimer s Disease Clinical Research Centre, 170 avenue de Casselardit, Gerontopole, 31059 Toulouse Cedex, INSERM UMR 1027, France
    Expert Opin Biol Ther 12:1077-86. 2012
  2. doi request reprint 'Clinical trials in Alzheimer's disease': immunotherapy approaches
    Julien Delrieu
    Alzheimer s Disease Clinical Research Centre, Gerontopole, Toulouse University Hospital, France INSERM 1027, France
    J Neurochem 120:186-93. 2012
  3. doi request reprint Sensory alien hand syndrome in corticobasal degeneration: a cerebral blood flow study
    Julien Delrieu
    Alzheimer s Disease Clinical Research Centre, Gerontopole, Toulouse University Hospital, Toulouse, France
    Mov Disord 25:1288-91. 2010
  4. doi request reprint [The Alzheimer's disease: how to estimate the impact of the pathology and the treatment?]
    Julien Delrieu
    Centre de Recherche Clinique sur la Maladie d Alzheimer, Gerontopole, Hôpital Universitaire de Toulouse, Toulouse, France INSERM U558, Toulouse, France
    Therapie 65:423-8. 2010
  5. doi request reprint Managing cognitive dysfunction through the continuum of Alzheimer's disease: role of pharmacotherapy
    Julien Delrieu
    Alzheimers Disease Clinical Research Centre, Gerontopole, Toulouse University Hospital, Toulouse, France
    CNS Drugs 25:213-26. 2011

Detail Information

Publications5

  1. doi request reprint Gantenerumab for the treatment of Alzheimer's disease
    Julien Delrieu
    Toulouse University Hospital, Alzheimer s Disease Clinical Research Centre, 170 avenue de Casselardit, Gerontopole, 31059 Toulouse Cedex, INSERM UMR 1027, France
    Expert Opin Biol Ther 12:1077-86. 2012
    ..Immunotherapy directed against the β-amyloid peptide may be capable of slowing the rate of disease progression. Gantenerumab is the first fully human anti-β-amyloid monoclonal antibody...
  2. doi request reprint 'Clinical trials in Alzheimer's disease': immunotherapy approaches
    Julien Delrieu
    Alzheimer s Disease Clinical Research Centre, Gerontopole, Toulouse University Hospital, France INSERM 1027, France
    J Neurochem 120:186-93. 2012
    ..Currently, several Aβ peptide immunotherapy approaches are under investigation but also against tau pathology...
  3. doi request reprint Sensory alien hand syndrome in corticobasal degeneration: a cerebral blood flow study
    Julien Delrieu
    Alzheimer s Disease Clinical Research Centre, Gerontopole, Toulouse University Hospital, Toulouse, France
    Mov Disord 25:1288-91. 2010
    ..We observed significant decrease of regional cerebral blood flow over the nondominant thalamus in sAHS+ compared to sAHS- patients. This result suggests the involvement of the nondominant thalamus in sAHS...
  4. doi request reprint [The Alzheimer's disease: how to estimate the impact of the pathology and the treatment?]
    Julien Delrieu
    Centre de Recherche Clinique sur la Maladie d Alzheimer, Gerontopole, Hôpital Universitaire de Toulouse, Toulouse, France INSERM U558, Toulouse, France
    Therapie 65:423-8. 2010
    ..However, at present no biomarker is validated as surrogate endpoint. It seems today indispensable to use them in the therapeutic tries so as to validate and standardize their methods of acquisition, measure and analysis...
  5. doi request reprint Managing cognitive dysfunction through the continuum of Alzheimer's disease: role of pharmacotherapy
    Julien Delrieu
    Alzheimers Disease Clinical Research Centre, Gerontopole, Toulouse University Hospital, Toulouse, France
    CNS Drugs 25:213-26. 2011
    ..There is currently insufficient evidence for recommending combination therapy in Alzheimer's disease...